Forty Seven, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Forty Seven, Inc..The latest application filed is for "depletion regimes for engineered t-cell or nk-cell therapy".

Company Profile

22.12.20

Forty Seven, Inc. - Foster City CA US
Forty Seven, Inc. - Menlo Park CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Depletion Regimes For Engineered T-cell Or Nk-cell Therapy App 20220288118 - Gibbs; Craig ; et al.	2022-09-15
Multispecific Agents For Treatment Of Cancer App 20220185905 - McCamish; Mark ; et al.	2022-06-16
Humanized Antibodies Against C-kit App 20220127358 - Liu; Jie ; et al.	2022-04-28
Genetically Modified Hspcs Resistant To Ablation Regime App 20220023348 - Gibbs; Craig ; et al.	2022-01-27
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies App 20210401979 - Majeti; Ravindra ; et al.	2021-12-30
Humanized antibodies against c-Kit Grant 11,208,482 - Liu , et al. December 28, 2	2021-12-28
Dosing parameters for CD47 targeting therapies to hematologic malignancies Grant 11,141,480 - Majeti , et al. October 12, 2	2021-10-12
Humanized, Mouse Or Chimeric Anti-cd47 Monoclonal Antibodies App 20210188976 - Chalons-Cottavoz; Marie ; et al.	2021-06-24
Humanized antibodies against c-Kit Grant 11,041,022 - Liu , et al. June 22, 2	2021-06-22
Anti-sirp-alpha Antibodies And Related Methods App 20210171654 - Liu; Jie ; et al.	2021-06-10
Anti-cd47 Based Treatment Of Blood Cancer App 20210147568 - Chao; Mark Ping ; et al.	2021-05-20
Humanized Antibodies Against C-kit App 20210122822 - Liu; Jie ; et al.	2021-04-29
Combination Therapies For Treating Myelodysplastic Syndromes And Acute Myeloid Leukemia App 20210115140 - Cao; Yinuo ; et al.	2021-04-22
Anti-SIRP-.alpha. antibodies and related methods Grant 10,961,318 - Liu , et al. March 30, 2	2021-03-30
Humanized, mouse or chimeric anti-CD47 monoclonal antibodies Grant 10,927,173 - Chalons-Cottavoz , et al. February 23, 2	2021-02-23
Treatment Of Ovarian Cancer With Anti-cd47 And Anti-pd-l1 App 20210047416 - Takimoto; Chris Hidemi Mizufune ; et al.	2021-02-18
Regimes For Co-administration Of Immunotherapeutic Agents Against C-kit And Cd47 App 20200369767 - Gibbs; Craig ; et al.	2020-11-26
Anti-CD47 Agent-Based Ovarian Cancer Therapy App 20200283520 - Takimoto; Chris Hidemi Mizufune ; et al.	2020-09-10
Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-SIRPalpha Antibody Therapy App 20200262918A1 -	2020-08-20
Humanized Antibodies Against C-kit App 20200165337 - Liu; Jie ; et al.	2020-05-28
Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRP.alpha. antibody therapy Grant 10,611,842 - Liu , et al.	2020-04-07
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer App 20190248915 - Chao; Mark Ping ; et al.	2019-08-15
Anti-SIRP-Alpha Antibodies and Related Methods App 20190119396 - Liu; Jie ; et al.	2019-04-25
Humanized, Mouse or Chimeric Anti-CD47 Monoclonal Antibodies App 20190023784 - Chalons-Cottavoz; Marie ; et al.	2019-01-24
Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-SIRPalpha Antibody Therapy App 20180037652 - Liu; Jie ; et al.	2018-02-08

Company Registrations

NCAGE Code	8H0Z5	FORTY SEVEN, INC.!DBA FORTY SEVEN
CAGE Code	8H0Z5	FORTY SEVEN, INC. FORTY SEVEN
S.A.M. Registration	8H0Z5 [80183664]	FORTY SEVEN, INC. FORTY SEVEN
SEC	0001667633	Forty Seven, Inc. of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.